A regulator-mandated study using nationwide registry data across Denmark, Sweden, and Norway found no increased pancreatic cancer risk among more than 97,000 semaglutide users compared with users of other diabetes drugs. The analysis directly addresses post-market safety questions that have persisted around GLP-1 therapies, using real-world longitudinal follow-up rather than trial-only surveillance. For clinicians and developers, the findings narrow uncertainty by tying exposure to observed incidence in population-level data. The result is likely to influence ongoing pharmacovigilance conversations and patient risk counseling around incretin-based treatments.